Back to today’s briefing

Story perspectives

Hims & Hers Partners with Novo Nordisk for Wegovy Access

4/30/2025

35 5

Summary

Hims & Hers Partners

Hims & Hers has joined forces with Novo Nordisk to make the weight loss drug Wegovy available via its telehealth platform, priced at $599 monthly. This partnership seeks to enhance access to FDA-approved obesity treatments as compounded versions are discontinued. Following the news, Hims & Hers stock skyrocketed by 35%, with Novo Nordisk shares climbing 3%.

Summary

Wegovy Lawsuits Escalate

Novo Nordisk's weight-loss drug Wegovy is under fire as users file lawsuits, alleging it led to irreversible vision loss due to undisclosed risks. Compounding concerns, a CDC study revealed that semaglutide was linked to nearly 25,000 emergency room visits for severe gastrointestinal problems, underscoring the urgent need for improved patient education and safety measures.

History

Historical Context

Hims & Hers' partnership with Novo Nordisk reflects a significant shift in healthcare delivery, similar to the telehealth expansion during the COVID-19 pandemic. This evolution highlights the increasing reliance on remote healthcare solutions, a trend that began in earnest in the 1990s but accelerated dramatically in recent years.

1 of 3

Hims & Hers Partners

Hims & Hers has joined forces with Novo Nordisk to make the weight loss drug Wegovy available via its telehealth platform, priced at $599 monthly. This partnership seeks to enhance access to FDA-approved obesity treatments as compounded versions are discontinued. Following the news, Hims & Hers stock skyrocketed by 35%, with Novo Nordisk shares climbing 3%.

1 / 3